The Diabetic Foot Ulcer market is expected to grow due to
an increase in diabetes cases, expected entry of emerging
therapies, and readily adoption of these novel
therapies.
LAS VEGAS, March 1, 2021 /PRNewswire/ -- DelveInsight's
"Diabetic Foot Ulcer (DFU) Market" report provides a thorough
comprehension of the Diabetic Foot Ulcer, historical and forecasted
epidemiology, and the Diabetic Foot Ulcer market trends in the 7MM
[the United States, EU5
(Germany, Spain, Italy,
France, and United Kingdom) and Japan]. The Diabetic Foot Ulcer market report
also proffers an analysis of recent Diabetic Foot Ulcer treatment
algorithm/practice, market drivers, market barriers, and unmet
medical needs.
Some of the vital points of the Diabetic Foot Ulcer
Market Research Report
- Diabetic Foot Ulcer (DFU) is one of the most
significant and devastating complications of diabetes mellitus, and
probably the major component of the diabetic foot. According to
American Podiatric Medical Association (APMA), diabetes is the
leading cause of non-traumatic lower extremity amputations in
the United States, and
approximately 14-24% of patients with diabetes who develop a
foot ulcer will require an amputation. Foot ulceration
precedes 85% of diabetes-related amputations.
- The gold standard for Diabetic Foot Ulcer treatment includes
debridement of the wound, management of any infection,
revascularization procedures when indicated, and off-loading of the
ulcer. Currently, the market is mainly dominated by
off-label generic drugs such as analgesics and
anti-infectives, around 78% of the current market is
captured by these two classes of drugs.
- There is only one drug, Regranex (Becaplermin), which
the FDA has approved. Regranex gel uses a Platelet-derived
growth factor (PDGF) for the Diabetic Neuropathic Ulcer treatment
formulated to act as a first-line treatment following effective
ulcer care. The US FDA had approved the biologics license
application of Becaplermin (OMJ Pharmaceuticals, Inc) in
December 1997.
- Market players such as Amniox (TissueTech), Helixmith Co.,
Ltd., Oneness Biotech Co., Ltd., Ticeba GmbH, RHEACELL GmbH &
Co. KG, and Lakewood-Amedex Inc, Aurealis Therapeutics, Biotherapy
Services, Microbion Corporation, Mallinckrodt, and many others are involved in
developing Diabetic Foot Ulcer drugs.
- The emerging therapies under development expected to provide
efficient therapeutic approaches with a novel mechanism of action
to treat Diabetic Foot Ulcer patients. Among the emerging
therapies, cryopreserved umbilical cord TTAX01 allograft
from Amniox Medical (a TissueTech) is expected to garner
the highest patient share owing to promising efficacy
signals shown in phase II trial and the company is well on track
with two-phase III multicenter randomized controlled clinical
trials.
For additional information on Market Impact by Therapies,
visit: Diabetic Foot Ulcer Treatment Market Analysis
A Diabetic Foot Ulcer is a complex chronic wound commonly in
type 1 and type 2 diabetes mellitus patients. Diabetes patients can
quickly develop foot ulcers and foot pain as they are a common
complication of poorly controlled diabetes, but good foot care can
help prevent them. As per DelveInsight's analysis, the total
Diabetic Foot Ulcer prevalent cases were 5,994,978 cases in
the 7MM (the United States, EU5
[Germany, France, Italy, Spain,
and the United Kingdom], and
Japan) in 2020 and are expected to
grow during the study period of 2018–2030.
For more information on Diabetic Foot Ulcer Market, click here @
Diabetic Foot Ulcer Market Infographic
The DFU Market Report provides historical as
well as forecasted epidemiological analysis segmented into:
- Total Prevalent Cases of Diabetic Foot Ulcer
- Total Diagnosed Cases of Diabetic Foot Ulcer
- Gender-specific cases of Diabetic Foot Ulcer
- Age-specific Cases of Diabetic Foot Ulcer
- Diabetic Foot Ulcer cases by severity/chronicity of wound
- Treated cases of Diabetic Foot Ulcer
Request sample report for more insights @ Diabetic Foot
Ulcer Market Size
Diabetic Foot Ulcer Therapeutics Market
The therapy goals for Diabetic Foot Ulcer patients are wound
closure, eradication of clinical evidence of infection, and the
avoidance of soft tissue loss and amputations.
Currently, Diabetic Foot Ulcer treatment strategies mainly
include non-surgical treatment for mild and moderate ulcers and
surgical treatment for ulcers classified as severe. Non-surgical
treatment options mainly include simple daily wound care, using
growth factors and skin substitutes for wound repair, antibiotics
for the deep infection, drainage, and cellulitis. Whereas surgical
treatment options mainly include debridement, removal of unhealthy
tissue, and vascular surgeries to induce better blood flow. The
development of growth factor for treatment represents a significant
therapeutic advance for diabetic neuropathic foot ulcers with
adequate blood supply.
Platelet-derived growth factor (PDGF) is one of the primary
growth factors involved in healing. Regranex (Becaplermin) is the
only drug, which uses PDGF and is approved by the US FDA. Regranex
(Becaplermin) is a topical gel labeled for adjunctive treatment of
stage III and IV diabetic neuropathic ulcers of the lower
extremities. Becaplermin is a recombinant human platelet-derived
growth factor; therefore, it promotes wound healing by enhancing
granulation tissue formation. This recombinant growth factor is
delivered in a topical aqueous-based sodium carboxymethylcellulose
(NaCMC) gel. Regranex gel is used to treat diabetic neuropathic
ulcers, formulated to act as a first-line treatment following
effective ulcer care.
Diabetic Foot Ulcer Emerging Therapies Along with Key
Players
The companies are working to assess challenges and seek
opportunities that could influence Diabetic Foot Ulcer R&D. The
therapies under development are focused on novel approaches to
treat Diabetic Foot Ulcer. Major players are involved in developing
Diabetic Foot Ulcer therapies.
- TTAX01 (Neox Cord 1K): Amniox
(TissueTech)
- Engensis (VM202; Donaperminogene Seltoplasmid):
Helixmith
- ON101 (WH-1): Oneness Biotech
- Allo-APZ2-DFU (ABCB5 positive MSCs): Rheacell (a
subsidiary of Ticeba)
- Bisphosphocin Nu-3: Lakewood-Amedex
- AUP1602-C: Aurealis Therapeutics
- RAPID Biodynamic PRP Haematogel: Biotherapy Services
- MBN-101 (Pravibismane): Microbion Corporation
- ExpressGraft (C9T1 Skin Tissue): Mallinckrodt
And many others.
Concluding thoughts on Diabetic Foot Ulcer Market Growth
Dynamics
The dynamics of the Diabetic Foot Ulcer market are anticipated
to change in the coming years because of the DFU Market
Drivers such as an increase in diabetes cases, a rich
emerging pipeline, the development of new treatment modalities, and
increased awareness across health care systems. However, the burden
of high cost in Diabetic Foot Ulcer treatment, post-operative
challenges in Diabetic Foot Ulcer patients, and unavailability of
specialists lead to restraints in Diabetic Foot Ulcer market
growth.
Scope of the Diabetic Foot Ulcer Market
Insight Report
- Geography Covered: 7MM - The
United States, EU5 (Germany, France, Italy, Spain,
and the United Kingdom),
Japan.
- Study Period: 3-year historical and 10-year forecasted
analysis (2018-2030).
- Diabetic Foot Ulcer Markets Segmentation: By
Geographies and By Diabetic Foot Ulcer Therapies
(Historical and Forecasted, Current and Upcoming)
- Leading Market Companies investigating its candidates
for Diabetic Foot Ulcer: Amniox (TissueTech),
Helixmith Co., Ltd., Oneness Biotech Co., Ltd., Ticeba GmbH,
RHEACELL GmbH & Co. KG, and Lakewood-Amedex Inc, Aurealis
Therapeutics, Biotherapy Services, Microbion Corporation,
Mallinckrodt, and several
others.
- Analysis: Comparative and conjoint analysis of emerging
therapies.
- Case Studies
- KOL's Views
- Analyst's View
Request for a Webex demo of the report @ Global Diabetic
Foot Ulcer Treatment Market Size
Table of Contents
1
|
Key Insights
on Diabetic Foot Ulcer
|
2
|
Executive Summary
of Diabetic Foot Ulcer
|
3
|
SWOT Analysis of
Diabetic Foot Ulcer
|
4
|
Diabetic Foot
Ulcer Market Share (%) Distribution Overview at a Glance: By
Country
|
5
|
Diabetic Foot
Ulcer Epidemiology and Market Methodology
|
6
|
Disease Background
and Overview: Diabetic Foot Ulcer
|
7
|
Diabetic Foot
Ulcer Diagnosis
|
8
|
Prevention of
Diabetic Foot Ulcer
|
9
|
DFU Diagnostic
Guidelines
|
10
|
Diabetic Foot
Ulcer Epidemiology and Patient Population
|
11
|
Diabetic Foot
Ulcer Epidemiology Scenario: 7MM
|
12
|
United
States DFU Epidemiology
|
13
|
EU5
Countries DFU Epidemiology
|
13.1
|
Germany
|
13.2
|
France
|
13.3
|
Italy
|
13.4
|
Spain
|
13.5
|
United
Kingdom
|
14
|
Japan DFU Epidemiology
|
15
|
Current
DFU Treatment Practices
|
16
|
Diabetic Foot
Ulcer Treatment and Prevention Guidelines
|
17
|
Unmet
Needs
|
18
|
Patient Journey
of Diabetic Foot Ulcer
|
19
|
Key Endpoints in
DFU Clinical Trials
|
20
|
Diabetic Foot
Ulcer Marketed Therapy
|
20.1
|
Regranex Gel
(Becaplermin): Smith & Nephew
|
21
|
Diabetic Foot
Ulcer Emerging Therapies
|
21.1
|
TTAX01 (Neox Cord
1K): Amniox (TissueTech)
|
21.2
|
Engensis (VM202;
Donaperminogene Seltoplasmid): Helixmith (formerly
known as
ViroMed)
|
21.3
|
ON101 (WH-1): Oneness
Biotech
|
21.4
|
Allo-APZ2-DFU (ABCB5
positive MSCs): Rheacell (a subsidiary of Ticeba)
|
21.5
|
Bisphosphocin Nu-3:
Lakewood-Amedex
|
21.6
|
AUP1602-C: Aurealis
Therapeutics
|
21.7
|
RAPID Biodynamic PRP
Haematogel: Biotherapy Services
|
21.8
|
MBN-101
(Pravibismane): Microbion Corporation
|
21.9
|
ExpressGraft (C9T1
Skin Tissue): Mallinckrodt
|
22
|
7MM
Diabetic Foot Ulcer Market Analysis
|
23
|
7MM
Diabetic Foot Ulcer Market Size
|
24
|
United States
Diabetic Foot Ulcer Market Size
|
25
|
EU-5 Diabetic Foot
Ulcer Market Size
|
25.1
|
Germany Market
Size
|
25.2
|
France Market
Size
|
25.3
|
Italy Market
Size
|
25.4
|
Spain Market
Size
|
25.5
|
United Kingdom Market
Size
|
26
|
Japan Diabetic
Foot Ulcer Market Size
|
27
|
Market Access and
Reimbursement of Diabetic Foot Ulcer
Therapies
|
28
|
Diabetic Foot
Ulcer Market Drivers
|
29
|
Diabetic Foot
Ulcer Market Barriers
|
30
|
Appendix
|
31
|
DelveInsight
Capabilities
|
32
|
Disclaimer
|
33
|
About
DelveInsight
|
Browse detailed TOC with charts, figures, tables @ DFU
Market Size Report
View Related
Reports
- Diabetic Foot Ulcers Epidemiology Forecast Analysis
DelveInsight's Diabetic foot ulcers (DFUs) - Epidemiology
Forecast 2030 report delivers an in-depth understanding of the
disease, historical, and forecasted epidemiology of Diabetic foot
ulcers (DFUs) in the United
States, EU5 (Germany,
France, Italy, Spain,
and the United Kingdom), and
Japan.
- Diabetic Foot Ulcers Pipeline Analysis
Diabetic Foot Ulcers Pipeline Insight, 2020 report by
DelveInsight outlays comprehensive insights of present clinical
development scenario and growth prospects across the Diabetic Foot
Ulcers market.
- Dementia with Diabetes Market Analysis
DelveInsight's Dementia with Diabetes - Market Insights,
Epidemiology and Market Forecast - 2030 report provides an in-depth
understanding of historical and forecasted epidemiology.
DelveInsight's Diabetes Market Insights, Epidemiology and Market
Forecast - 2030 report provides thorough insights on epidemiology
and market trends.
- Diabetic Foot Market Analysis
DelveInsight's Diabetic Foot - Market Insights, Epidemiology,
and Market Forecast - 2030 report provides a detailed overview of
the disease and a depth understanding of historical and forecasted
epidemiology.
- Diabetic Gastroparesis Market Analysis
Diabetic Gastroparesis Market Research Report presents a
detailed analysis of the market listing Diabetic Gastroparesis
Epidemiology, Drug therapies.
- Diabetic Ketoacidosis Market Analysis
DelveInsight's Diabetic Ketoacidosis (DKA) - Market Insights,
Epidemiology and Market Forecast - 2030 report provides a detailed
overview of the disease and a depth understanding of historical and
forecasted epidemiology.
- Diabetic Kidney Disease Market Analysis
DelveInsight's Diabetic Kidney Disease (DKD) - Market Insights,
Epidemiology and Market Forecast - 2030 report provides a detailed
overview of the disease and a depth understanding of historical and
forecasted epidemiology.
- Diabetic Macular Edema Market Analysis
DelveInsight's Diabetic Macular Edema (DME) - Market Insights,
Epidemiology and Market Forecast - 2030 report provides a detailed
overview of the disease and a depth understanding of historical and
forecasted epidemiology.
- Diabetic Nephropathy Market Analysis
DelveInsight's Diabetic Nephropathy - Market Insights,
Epidemiology, and Market Forecast - 2030 report provides a detailed
overview of the disease.
- Diabetic Neuropathy Market Analysis
DelveInsight's "Diabetic Neuropathy - Market Insights,
Epidemiology, and Market Forecast-2030" report delivers an in-depth
understanding of Diabetic Neuropathy, historical and forecasted
epidemiology.
- Diabetic Peripheral Neuropathy Market Analysis
DelveInsight's Diabetic Peripheral Neuropathy - Market Insights,
Epidemiology and Market Forecast - 2030 report provides an in-depth
understanding of historical and forecasted epidemiology.
- Diabetic Retinopathy Market Analysis
DelveInsight's Diabetic Retinopathy Market Insights,
Epidemiology and Market Forecast 2030 report provides an overview
of the disease & understanding of historical & forecasted
epidemiology.
- Diabetes Pen Market Analysis
Diabetes Pen Market Insights, Competitive Landscape and Market
Forecast-2025 report delivers an in-depth understanding of the
Diabetes Pen Market and the historical and forecasted
epidemiology.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market
Research firm focused exclusively on life sciences. It supports
Pharma companies by providing end to end comprehensive solutions to
improve their performance.
Contact Us:
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com
Logo:
https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg